HR 5133
116th Congress
House
Commerce
Administrative remedies
Civil actions and liability
Competition and antitrust
Consumer affairs
Drug safety, medical device, and laboratory regulation
Federal Trade Commission (FTC)
Health care costs and insurance
Inflation and prices
Intellectual property
Judicial review and appeals
Manufacturing
Prescription drugs
Affordable Prescriptions for Patients Through Promoting Competition Act of 2019
Introduced: November 18, 2019
See on congress.gov
Everywhere this bill has been
8 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 24, 2020
Placed on the Union Calendar, Calendar No. 578.
Dec 24, 2020
Reported by the Committee on Judiciary. H. Rept. 116-695.
Nov 21, 2019
Ordered to be Reported.
Nov 21, 2019
Committee Consideration and Mark-up Session Held.
Nov 19, 2019
Subcommittee on Antitrust, Commercial, and Administrative Law Discharged.
Nov 18, 2019
Referred to the House Committee on the Judiciary.
Nov 18, 2019
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Nov 18, 2019
Introduced in House
Plain-English summary
Affordable Prescriptions for Patients Through Promoting Competition Act of 2019
This bill prohibits, subject to certain exceptions, the practice of product hopping, which is presumed when a drug manufacturer obtains removal of a drug from the Food and Drug Administration's approved drug list, discontinues a drug, or markets a reformulation of an already approved drug during a certain period after which the manufacturer has been notified that a competing drug manufacturer has applied for generic drug approval.
What's happening now
Placed on the Union Calendar, Calendar No. 578.
Committees of jurisdiction
2